Dose-dependent pharmacokinetics of a new reversible proton pump inhibitor, DBM-819, after intravenous and oral administration to rats: Hepatic first-pass effect

Biopharmaceutics and Drug Disposition

Volumn 22, Issue 3, 2001, Pages 119-128

  Kim, Eun J ^a   Kim, Sun O ^b   Lee, Dong H ^b   Lim, Hong ^b   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b Dongbu Hannong Chemical Co   (South Korea)

Author keywords

DBM 819; Hepatic first pass effect; Pharmacokinetics; Rats

Indexed keywords

1 (2 METHYL 4 HYDROXYPHENYL) 4 [(3 HYDROXYPROPYL)AMINO] 6 METHYL 2,3 DIHYDROPYRROLO[3,2 C]QUINOLINE; 1 (2 METHYL 4 METHOXYPHENYL) 4 [(2 HYDROXYETHYL) AMINO] 6 O (2,2,2 TRIFLUOROETHYL) 2,3 DIHYDROPYRROLO[3,2 C]QUINOLINE; 1 (2 METHYL 4 METHOXYPHENYL) 4 [(3 HYDROXYPROPYL)AMINO] 5 OXY 6 HYDROXYMETHYL 2,3 DIHYDROPYRROLO[3,2 C]QUINOLINE; 1 (2 METHYL 4 METHOXYPHENYL) 4 [(3 HYDROXYPROPYL)AMINO] 6 METHYL 8 HYDROXY 2,3 DIHYDROPYRROLO [3,2 C]QUINOLINE; 1 (2 METHYL 4 METHOXYPHENYL) 4 ACETAMIDO 6 METHYL 2,3 DIHYDROPYRROLO[3,2 C]QUINOLINE; 1 (2 METHYL 4 METHOXYPHENYL) 4 AMINO 6 METHYL 2,3 DIHYDROPYRROLO[3,2 C]QUINOLINE; 2,3 DIHYDRO 4 (3 HYDROXYPROPYLAMINO) 1 (4 METHOXY 2 METHYLPHENYL) 6 METHYLPYRROLO[3,2 C]QUINOLINE; DRUG METABOLITE; KR 60461; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG STRUCTURE; FIRST PASS EFFECT; GASTROINTESTINAL TRACT; LIVER; MALE; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENOUS; LIVER; MALE; PROTON PUMPS; PYRROLES; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 0035663659     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.264     Document Type: Article

References (15)

1. +)-ATPase
2. +)-ATPase. 1. 1-Aryl-4-methyl pyrrolo[3, 2-c]quinolines as conformationally restrained analogues of 4-(arylamino) quinolines
3. Pharmacokinetics and pharmacodynamics of azosemide after intravenous and oral administration to rats: Absorption from various GI segments
4. Species differences in pharmacokinetics of a hepatoprotective agent, YH439, and its metabolites, M4, M5, and M7 after intravenous and oral administration to rats, rabbits, and dogs
5. Liver and gastrointestinal first-pass effects of azosemide in rats
6. Kinetics of aluminum in rats. III: Effect of route of administration
7. Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve
8. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition
9. New calculation method for mean apparent drug volume of distribution and application to rational dosage regimen
10. Pharmacokinetics of diazepam following multiple-dose oral administration to healthy human subjects
11. New calculation method of mean total body clearance of drugs and its application to dosage regimens
12. Physiological parameters in laboratory animals and humans
13. Blood partition and protein binding of a new reversible proton pump inhibitor, DBM-819
14. Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolism